[{"address1": "321 Harrison Avenue", "address2": "Suite 900", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 949 2643", "website": "https://www.monterosatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation (I&I) indications, oncology, and genetic diseases. The company has developed QuEEN, a discovery engine, to enable its unique target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 134, "companyOfficers": [{"maxAge": 1, "name": "Dr. Markus  Warmuth M.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 970830, "exercisedValue": 0, "unexercisedValue": 4132003}, {"maxAge": 1, "name": "Mr. Philip  Nickson J.D., Ph.D.", "age": 44, "title": "Chief Business & Legal Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 704801, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Filip  Janku M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 743800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Champoux", "title": "Chief Operating Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Castle Ph.D.", "age": 52, "title": "Chief Data & Information Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Townson Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Funderburk", "title": "Senior VP and Head of IR & Strategic Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Magnus  Walter DPHIL", "title": "Senior Vice President of Drug Discovery", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Dunn", "age": 57, "title": "Senior VP & Corporate Controller", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.89, "open": 3.75, "dayLow": 3.65, "dayHigh": 3.9695, "regularMarketPreviousClose": 3.89, "regularMarketOpen": 3.75, "regularMarketDayLow": 3.65, "regularMarketDayHigh": 3.9695, "payoutRatio": 0.0, "beta": 1.533, "forwardPE": -2.6333334, "volume": 1142231, "regularMarketVolume": 1142231, "averageVolume": 746998, "averageVolume10days": 761370, "averageDailyVolume10Day": 761370, "bid": 3.88, "ask": 3.98, "bidSize": 7, "askSize": 3, "marketCap": 242963712, "fiftyTwoWeekLow": 3.21, "fiftyTwoWeekHigh": 12.4, "priceToSalesTrailing12Months": 3.2128708, "fiftyDayAverage": 5.9922, "twoHundredDayAverage": 6.08505, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -86470208, "profitMargins": -0.96136004, "floatShares": 33917745, "sharesOutstanding": 61509800, "sharesShort": 7033824, "sharesShortPriorMonth": 8029011, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.1144, "heldPercentInsiders": 0.00704, "heldPercentInstitutions": 1.02236, "shortRatio": 13.4, "shortPercentOfFloat": 0.2087, "impliedSharesOutstanding": 61509800, "bookValue": 3.625, "priceToBook": 1.0896552, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -72700000, "trailingEps": -0.98, "forwardEps": -1.5, "enterpriseToRevenue": -1.143, "enterpriseToEbitda": 1.185, "52WeekChange": -0.4740346, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 3.95, "targetHighPrice": 20.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.125, "targetMedianPrice": 16.5, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 372148992, "totalCashPerShare": 6.05, "ebitda": -72991000, "totalDebt": 42715000, "quickRatio": 2.372, "currentRatio": 2.405, "totalRevenue": 75622000, "debtToEquity": 19.16, "revenuePerShare": 1.023, "returnOnAssets": -0.13655, "returnOnEquity": -0.36152, "grossProfits": -37241000, "freeCashflow": 81974000, "operatingCashflow": 41996000, "grossMargins": -0.49245998, "ebitdaMargins": -0.96521, "operatingMargins": 0.21441999, "financialCurrency": "USD", "symbol": "GLUE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.5424149, "regularMarketPrice": 3.95, "shortName": "Monte Rosa Therapeutics, Inc.", "longName": "Monte Rosa Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1743798512, "regularMarketTime": 1743796802, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624541400000, "postMarketChangePercent": 1.26582, "postMarketPrice": 4.0, "postMarketChange": 0.05, "regularMarketChange": 0.059999943, "regularMarketDayRange": "3.65 - 3.9695", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 746998, "fiftyTwoWeekLowChange": 0.74, "fiftyTwoWeekLowChangePercent": 0.23052959, "fiftyTwoWeekRange": "3.21 - 12.4", "fiftyTwoWeekHighChange": -8.45, "fiftyTwoWeekHighChangePercent": -0.6814516, "fiftyTwoWeekChangePercent": -47.40346, "epsTrailingTwelveMonths": -0.98, "epsForward": -1.5, "epsCurrentYear": -1.53712, "priceEpsCurrentYear": -2.5697408, "exchange": "NMS", "messageBoardId": "finmb_690261281", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": -2.0421999, "fiftyDayAverageChangePercent": -0.3408097, "twoHundredDayAverageChange": -2.13505, "twoHundredDayAverageChangePercent": -0.3508681, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-24", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "displayName": "Monte Rosa Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]